Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AβYSS: Beta Blocker Interruption Post-MI
NCT03498066Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol in myocardial infarction (MI) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Major Adverse Cardiovascular Events at 3 years. Started Aug 2018; status: completed.
02
Drugs
carvedilol
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT03498066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03498066.